

August 29, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

**Company Code No. AUROPHARMA** 

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Completion of US FDA Inspection at Unit-I of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

The United States Food and Drug Administration (US FDA) inspected Unit-I, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Borpatla Village, Hatnoor Mandal, Sangareddy District, 502296, Telangana from August 21 to August 29, 2025.

At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported. We will respond to the US FDA within the stipulated timelines.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

The details of action initiated by US FDA in the prescribed format as required under Regulation 30 of the SEBI Listing Regulations are enclosed herewith as **Annexure**.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

## **AUROBINDO PHARMA LIMITED**

(CIN: L24239TG1986PLC015190)

www.aurobindo.com



## **Annexure**

S.No	Particulars	Details
1.	Name of the authority	U.S. Food and Drug Administration (US FDA), USA
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (US FDA) inspected Unit-I, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Borpatla Village, Hatnoor Mandal, Sangareddy District, 502296, Telangana from August 21 to August 29, 2025.
		At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported. We will respond to the US FDA within the stipulated timelines.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	August 29, 2025
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported. We will respond to the US FDA within the stipulated timelines.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the Company's financials or operations due to the said action.

## **AUROBINDO PHARMA LIMITED**

(CIN: L24239TG1986PLC015190)

www.aurobindo.com